Showing posts with label biotechnology. Show all posts
Showing posts with label biotechnology. Show all posts

Wednesday, 1 August 2012

Switzerland in London for the Olympics - and Life Sciences

A small part of London has been transformed into Switzerland for the duration of the London Olympics. Well, to be fair, it is one building: but what a building! Glaziers Hall, the headquarters of the wonderfully-named Worshipful Company of Glaziers, has temporarily become "House of Switzerland UK 2012": the Swiss Government's hospitality centre for the duration of the Games. It is tempting to speculate just how much the Swiss must have paid the glaziers to get out of town for the summer, for their building has a delightful and convenient location, sandwiched between Southwark Cathedral and the river. Even the much hyped Olympic crowds at London Bridge station failed to materialise, at least when I was there on Day 4 of the Games, at mid-day and latish in the evening.

But what has this to do with biology, or journalism, or indeed any of the usual topics of this blog? Showing that biotechnologists are not above taking advantage of the networking opportunities offered by the Olympics, the canton of Zurich organised a very interesting Life Science Day at the House of Switzerland on 30 July. The Day, more precisely a long afternoon, was divided into three sessions. The first, organised by the EU HealthTIES consortium, presented some of the most important scientific and technical advances that are likely to affect healthcare in the next decades.

The HealthTIES consortium links biotech and health organisations in five European regions - Zurich (of course); Oxford ans its environs; BioCat in Catalonia, Spain; Medical Delta in the Netherlands; and Ëszak-Alföld in Hungary - aiming to promote innovation in technology for healthcare through collaboration. The first session brought together experts from Zurich, Oxford and Hungary to discuss some of these innovations and their implications for policy and ethics. It was particularly interesting for me to hear Hagan Bayley from the University of Oxford, whose academic research I had recently reported on for the Institute of Structural and Molecular Biology at Birkbeck and UCL, wearing his entrepeneurial hat to discuss the promise and implications of the $1000 Genome. Highlights from other UK speakers included Lord Brennan QC describing his own heart attack as a preface to a talk on health policy and Peter Walton's presentation of the clinical benefits of the UK's Adult Cardiac Surgery Database.

The second session brought the focus more firmly on to Switzerland, with presentations from five companies located in the Zurich region. Four of these were biotechs: EMPA, which manufactures biodegradable "plastics" from chemicals synthesised by micro-organisms; INSPHERO develops three-dimensional cell cultures for drug testing; Xeltis is developing methods to grow heart valves and blood vessels from a patient's own cells, and Virometrix is involved in vaccine design. The fifth presentation was by a finance company, SIX Swiss Exchange.

The final session was badged as part of the UK co-organiser One Nucleus' BioWednesday series of informal discussions and networking meetings. One Nucleus is a membership organisation for biotech companies and professionals in the greater London and Cambridge areas. This "BioWednesday on a Monday" took the form of a discussion of the characteristics and benefits of a successful biotech cluster, taking Zurich and London / Cambridge as examples. The combined London / Cambridge cluster is about twice the size of the one centred on Zurich, with 167 biotech companies compared to Zurich's 87. A lively discussion led by panellists from both countries cited features of successful clusters that included quality of life (with one Swiss panellist describing his whole country as "a biotech cluster with recreational add-ons"); communication links; and a mixture of different types of company with universities and teaching hospitals. Not surprisingly, the one negative feature of the locations much cited by delegates from both countries was their high costs.

An excellent "standing dinner" with wine brought this very worthwhile meeting to its close before we all braved the Olympic traffic home.

Monday, 19 September 2011

Thing 15: Linked In

Oh dear. I'm going to have to stop counting Cam 23.0 in weeks - I'm already over a month behind, and at this rate it may be Christmas before I finish. I hope that no one's going to throw me out of the party on Thursday...

But I have finally come to Linked In - getting on for a month after its fellow "Week 8" Thing, Facebook. I have had an account on Linked In for well over four years - much longer than my Facebook account, and, in fact, so long that I can't remember when I joined. But I've come to blog about it, rather than skipping to a less familiar Thing (or even Extra Thing) because I have finally got round to updating my profile with such relative basics as a photo and a link to my Twitter account. Perhaps this post should have been named "Procrastination".



When the 2010 version of 23 Things reached social networking sites, Aidan mentioned my observation that, of the three communities I consider myself at least a part-time member of, biotech professionals choose Linked In but science communicators and educationalists congregate on Twitter. I still have little idea why. To my eye, Linked In seems more slick and professional than Twitter (let alone Facebook), less inconsequential, but also, perhaps, a teeny bit duller. It is strictly a site for professional business, with most of the updates appearing on a Linked In timeline being new connections and job changes. And I have used it for a small number of pieces of real professional business. At one end of the scale, a comment on a Linked In group led me to be invited to give a careers talk - not big money or even little money, only expenses and canapes, but something I find rather fun. At the other, I spotted a contract as the in-house science writer for an immunology company, and was almost appointed only to part amicably after realising that the required commitment of a day a week in Oxford was just too much for me

If anyone were to ask my advice on how to get to grips with Linked In - and looking at my profile this is still rather unlikely - I would recommend a guy called Will Kintish. He is a small, unassuming ex-accountant, and one of the best networkers and trainers I have ever come across. His workshops can be fairly expensive (it is possible to find subsidised ones, and I was fortunate enough to attend one such earlier this year) but the combination of entertainment with useful, and memorable, networking tips may be well worth a substantial investment. And he is an evangelist for the value of social networking ("not just for kids") and for Linked In in particular. Check out his Linked In website - it's well worth a visit. I would suggest that you start with the four-minute video.


But I imagine that librarianship has more in common with communication and education than with biotech, but I may be wrong. If this hunch is correct, and my hunch about the three communities is correct (and these combine into a pretty big IF) then I would guess Twitter to be many librarians' network of choice. Is this true for you?